Aspire Biopharma (NASDAQ:ASBP) Stock Price Up 5.9% – Should You Buy?

Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP)’s share price was up 5.9% on Tuesday . The stock traded as high as $8.80 and last traded at $8.27. 28,864 shares changed hands during trading, a decline of 10% from the average daily volume of 32,211 shares. The stock had previously closed at $7.81.

Analysts Set New Price Targets

Separately, Weiss Ratings raised Aspire Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, August 14th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Aspire Biopharma currently has a consensus rating of “Sell”.

Aspire Biopharma Trading Up 1.1%

The stock has a market capitalization of $11.80 million, a P/E ratio of -0.12 and a beta of 0.11. The company has a 50-day moving average price of $6.82 and a 200 day moving average price of $16.33.

Institutional Trading of Aspire Biopharma

A number of institutional investors have recently modified their holdings of the company. CIBC Bancorp USA Inc. bought a new position in shares of Aspire Biopharma during the 3rd quarter worth approximately $28,000. Jane Street Group LLC lifted its position in Aspire Biopharma by 625.8% during the second quarter. Jane Street Group LLC now owns 152,552 shares of the company’s stock valued at $41,000 after acquiring an additional 131,533 shares during the last quarter. Finally, XTX Topco Ltd boosted its stake in Aspire Biopharma by 853.2% in the fourth quarter. XTX Topco Ltd now owns 265,471 shares of the company’s stock valued at $35,000 after acquiring an additional 237,620 shares in the last quarter. 19.17% of the stock is currently owned by institutional investors.

Aspire Biopharma Company Profile

Aspire Biopharma Inc is a specialty pharmaceutical company dedicated to developing and commercializing inhaled therapeutics for cardiopulmonary emergencies and respiratory diseases. The firm leverages proprietary formulation and drug-delivery technologies to repurpose established active pharmaceutical ingredients, aiming to enhance onset of action and improve patient convenience in acute settings. Aspire’s focus on pulmonary administration differentiates its approach from traditional oral or injectable treatments for asthma, allergic reactions, and other respiratory conditions.

The company’s lead asset is a reformulated metered-dose inhaler version of epinephrine designed to serve as an over-the-counter or prescription rescue therapy for acute bronchospasm and anaphylaxis.